藥品_產(chǎn)品搜索_第100頁_醫(yī)化信息網(wǎng)

當(dāng)前位置: 首頁 » 產(chǎn)品 » 搜索

Doxorubicin (hydrochloride)
Doxorubicin Hcl(Adriamycin) is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptos
2016-01-06 10:45 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

1800.00/100mg
0100mg起訂

WP1130
WP1130(Degrasyn) is a novel selective small molecular deubiquitinase (USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor a
2016-01-06 10:43 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

1252.00/5mg
05mg起訂

OF-1
OF-1 is a selective BRPF1B and BRPF2 bromodomain inhibitor with Kd values of 100 nM/500 nM for BRPF1B/BRPF2; 39-fold sel
2016-01-06 10:42 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

850.00/5mg
05mg起訂

Inauhzin
Inauhzin(INZ) is a novel small molecule that effectively reactivates p53 by inhibiting SIRT1 activity, promotes p53-depe
2016-01-06 10:40 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

1250.00/10mg
010mg起訂

β-Lapachone
-Lapachone(ARQ-501; beta-lapachone) is a naturally occurring quinone obtained from the bark of the lapacho tree (Tabebui
2016-01-06 10:38 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

600.00/10mg
010mg起訂

Dolastatin 10
Dolastatin 10(DLS 10;NSC 376128) is a potent antimitotic peptide from a marine animal, strongly inhibits microtubule ass
2016-01-06 10:37 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

13252.00/5mg
05mg起訂

Vincristine (sulfate)
Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 M.Target: Mi
2016-01-06 10:35 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

3162.00/100mg
0100mg起訂

Rucaparib (phosphate)
Rucaparib phosphate(AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1, also showing binding af
2016-01-06 10:33 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

884.00/5mg
05mg起訂

Mitomycin C
Mitomycin C is a DNA crosslinking agent that inhibits DNA synthesis and induces apoptosis in a variety of cells.IC50 Val
2016-01-06 10:32 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

818.00/10mg
010mg起訂

Rucaparib
Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1, also showing binding affinity to
2016-01-06 10:29 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

4938.00/50mg
050mg起訂

Oxaliplatin
Oxaliplatin inhibits DNA synthesis by conforming DNA adducts.IC50 Value:Target: DNA crosslinkerin vitro: The main mechan
2016-01-06 10:28 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

512.00/50mg
050mg起訂

Valproic acid
Valproic acid, a histone deacetylase (HDAC) inhibitor (IC50=10 uM in Hela cell, 24h) has an anticancer effect.IC50 Value
2016-01-06 10:26 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

800.00/5g
05g起訂

Gemcitabine
Gemcitabine(LY-188011; NSC 613327) is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIA
2016-01-06 10:24 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

720.00/100mg
0100mg起訂

Epirubicin (hydrochloride)
Epirubicin Hcl, a semisynthetic L-arabino derivative of doxorubicin, is an antineoplastic agent by inhibiting Topoisomer
2016-01-06 10:23 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

5675.00/100mg
0100mg起訂

JNJ-7706621
JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing 6-fold selectivit
2016-01-06 10:21 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

1507.00/5mg
05mg起訂

PF-06380101
PF-06380101 is a novel cytotoxic Dolastatin 10 analogue; with excellent potencies in tumor cell proliferation assays and
2016-01-06 10:18 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

15000.00/5mg
05mg起訂

Etoposide
Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.Target: TopoisomeraseApproved: 1983E
2016-01-06 10:16 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

2000.00/500mg
0500mg起訂

LY2334737
LY2334737 is an orally available prodrug of gemcitabine which is a nucleoside analog used as chemotherapy.IC50 Value:Tar
2016-01-06 10:14 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

12369.00/100mg
0100mg起訂

EPZ-6438
EPZ-6438 is a potent, selective, and orally bioavailable small-molecule inhibitor of EZH2 enzymatic activity with Ki val
2016-01-06 10:13 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]

948.00/5mg
05mg起訂

JW 55
JW 55 is an inhibitor of the PARP domain of tankyrase 1 and 2 (TNKS1/2).公司介紹：MedChemExpress(MCE)專注于各種抑制劑、
2016-01-06 10:11 [上海]
上海皓元生物醫(yī)藥科技有限公司 [已核實]